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Impact of published clinical outcomes data: case study in
NHS hospital trusts
Russell Mannion, Maria Goddard
Abstract
Objective To examine the impact of the publication
of clinical outcomes data on NHS Trusts in Scotland
to inform the development of similar schemes
elsewhere.
Design Case studies including semistructured
interviews and a review of background statistics.
Setting Eight Scottish NHS acute trusts.
Participants 48 trust staff comprising chief executives,
medical directors, stroke consultants, breast cancer
consultants, nurse managers, and junior doctors.
Main outcome measures Staff views on the benefits
and drawbacks of clinical outcome indicators
provided by the clinical resource and audit group
(CRAG) and perceptions of the impact of these data
on clinical practice and continuous improvement of
quality.
Results The CRAG indicators had a low profile in the
trusts and were rarely cited as informing internal
quality improvement or used externally to identify
best practice. The indicators were mainly used to
support applications for further funding and service
development. The poor effect was attributable to a
lack of professional belief in the indicators, arising
from perceived problems around quality of data and
time lag between collection and presentation of data;
limited dissemination; weak incentives to take action;
a predilection for process rather than outcome
indicators; and a belief that informal information is
often more useful than quantitative data in the
assessment of clinical performance.
Conclusions Those responsible for developing
clinical indicator programmes should develop robust
datasets. They should also encourage a working
environment and incentives such that these data are
used to improve continuously.
Introduction
The public dissemination of standardised data on clini›
cal outcomes is now established practice in many
health systems. In the United States, where public
reporting is most advanced, comparative information
on performance in the form of report cards, provider
profiles, and consumer reports has been released for
over a decade.1–3 In Europe, Scotland has been at the
forefront of public disclosure. Since 1994 the Scottish
Executive has published clinical outcome indicators
collected by the clinical resource and audit group
(CRAG) for all Scottish NHS acute trusts and health
boards. More recently, clinical performance data have
been published for trusts in England and Wales as part
of the NHS performance assessment framework.
A postal questionnaire survey conducted by the
Scottish Executive in 1997 indicated that the CRAG
indicators published in Scotland were of some
practical value to health professionals and, in a few
instances, had helped to bring about a change in clini›
cal practice. On the whole, however, the survey found
that the indicators had little effect on behaviour.4 We
present the key findings of a study designed to examine
the impact of the publication of these data on provider
organisations. The CRAG indicators are similar to
those now published more widely within the rest of the
United Kingdom, and therefore an analysis of the
Scottish experience may help with the implementation
of such programmes elsewhere.
The CRAG indicators are compiled and dissemi›
nated by the Scottish Executive. Seven reports have
been published detailing 38 clinical indicators for
named trusts and health boards in Scotland. It is
important to note that the CRAG indicators are not
part of a formal framework of performance assess›
ment. Since the indicators were first published the
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Scottish Executive has emphasised that they should
not be used to make definitive judgments on the
performance or quality of services.
The indicators vary by specialty but have some
common features:
x They are based on a linked dataset comprising
inpatient hospital episode statistics, the 1991 census
small area statistics, and recorded deaths
x To minimise the role of random year on year varia›
tion each indicator spans a period of at least three
years
x The indicators are standardised to control for
aspects of case mix that can be identified on the basis of
existing data. They are also standardised, when appro›
priate, for deprivation5 or the principal diagnosis of
any hospital admissions in the previous five years, or
both.
Methods
Selection and interview strategy
We considered that the most appropriate methods for
explaining in detail the use of the CRAG indicators
would be case studies of trusts comprising semistruc›
tured interviews with key staff and a review of
background documentation. We selected eight trusts,
reflecting a range of sizes (income and number of
beds), geographical area (city, town, rural), and
previous “performance” on the CRAG indicators
(table). While the case studies covered the full range of
published indicators, for the purposes of obtaining
more in depth analysis we focused on two clinical spe›
cialties: one published at health board level (five year
survival in women with breast cancer) and one
published for each trust (30 day survival after
emergency admission for stroke).
Interviews were undertaken with chief executives,
medical directors, consultants with responsibility for
breast cancer services, consultants with responsibility
for stroke services, nurse managers, and junior doctors
(eight of each). The interviews were semistructured,
tape recorded, and transcribed before analysis.
Analysis
We thought that clinical indicators would be more
likely to generate action when the data are perceived to
be credible and up to date and when staff believe they
are meaningful and important. Similarly, we assumed
that action would be more likely to be generated when
the external environment facilitates and supports
change through strategies such as targeted dissemina›
tion, staff training in the use of data, and a framework
of incentives.
We analysed interview transcripts using the qualita›
tive methods of content analysis.6 After an initial scru›
tiny of the transcripts we identified several preliminary
themes under broad headings to reflect our prior
hypotheses. We then collected together passages under
each identified theme and cross referenced them
according to the site and the type and grade of staff. We
also analysed the data to assess whether our findings
were related to characteristics of trusts (for example,
size, geographical location, and performance on the
chosen indicators).
Results
Impact on behaviour and practice
The CRAG indicators had a “low profile” in all trusts
and were rarely cited by staff as the primary drivers of
quality improvement or sharing best practice between
organisations. In six trusts the CRAG indicators were
reported to have stimulated some action in relation to
breast cancer or stroke services, but such action was
restricted to checking and auditing the quality of the
data rather than direct action to improve delivery of
service (table).
The indicators were seldom used in isolation when
service changes were being considered and were
typically augmented with more detailed local data. The
main use to which the CRAG data were put was to add
further weight and background evidence to applications
for additional funding, either within the trust or to the
health board. In four trusts the CRAG data were cited as
useful background information to support the case for a
Impact of CRAG data on eight NHS hospital trusts (breast cancer and stroke services)
1997
income
(£ millions)
No of
beds Location
Stroke Breast cancer
Indicator* Reported impact of indicator Indicator* Reported impact of indicator
1 <50 <500 Town Worse CRAG data stimulated further audit and
introduction of patient protocols. Indicators
used as background information to make
successful case for establishing stroke unit
Average No obvious impact
2 >50 >500 Town Average Provided background information to support
case for new stroke unit
Average No obvious impact
3 >50 >500 City Average No obvious impact Average CRAG data one of background reasons
why £0.5 million invested in additional
staff and facilities; one stop clinic set up
4 >100 >1000 Town Worse Data used alongside other relevant
information to argue for new stroke unit;
stimulated audit of data
No reported impact
5 >50 >500 Town Average CRAG data one of background factors used
successfully to make case for stroke unit;
stimulated data audit
Average Background factor in setting up of new
breast clinics and increase in
mammography services
6 >100 >1000 City Average No obvious impact Average Used as background information to inform
development of services
7 >50 >500 Rural Average No obvious impact Average No impact
8 >50 >500 Rural Average No obvious impact on changing stroke
services. Satisfactory performance on CRAG
data used as reason by local health board to
decline additional funding
Average Interesting background information but not
specifically identified with changing
practice
*Compared with average for Scotland.
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stroke unit. Our findings do not seem to be related to the
characteristics of trusts in terms of size, geographical
location, or performance on the indicators.
Exploring the reasons for low impact
There are several possible explanations for the limited
impact of the indicators (box).
Credibility—Many staff, in particular the consultants,
had serious concerns over the quality of the data used to
compile the CRAG indicators, and because of this the
data lacked credibility. Problems centred on issues of
data quality, including incomplete and inconsistent cod›
ing and inadequate adjustment for variation in case mix.
Timeliness—The elapsed time between collection
and publication of data was a major drawback to the
indicators being used in a meaningful way for continu›
ous quality improvement. In many cases the CRAG
indicators are at least a year out of date and consider›
ably more for some indicators such as breast cancer.
Awareness—Recent studies have suggested that if
clinical indicators are to be useful in supporting quality
improvement they need to be transmitted and commu›
nicated to staff at all levels of the organisation.7 However,
we found that although consultants and chief executives
were aware of the data, most nurse managers and junior
doctors reported that they had little or no knowledge of
the indicators. Only one trust disseminated these data to
nurse managers and junior doctors.
Training and facilitation—None of the trusts ran spe›
cific training or education programmes on the appro›
priate use and interpretation of clinical indicators, and
no single person within each trust was identified as
being responsible for supporting their use throughout
the organisation.
Incentives—The indicators are not part of a formal
system of performance assessment, with an incentive
mechanism attached to performance. However, some
staff acknowledged that informal incentives that had an
effect on status and professional reputation were
sometimes associated with relative performance on the
indicators.
Supplementary information—Some staff thought that
informal information transmitted through channels
and professional networks was more useful than
formal indicators in capturing important aspects of
performance that defy simple codification. In particu›
lar, the clinical indicators were often viewed as too
unwieldy and out of date to spot poor clinical
performance in staff and that “whistle blowing” and
“word of mouth” were the most common channels for
alerting initial concern.
Process or outcome indicators—Many members of staff
preferred process rather than outcome indicators as
they were thought to be more reliable, up to date, and
easier to measure and to provide better guidance on
what specific actions are needed to improve the quality
of care.
External accountability—Little pressure was exerted
by outside bodies on trusts for them to “perform” well
on the CRAG indicators. On the whole, health boards
did not hold trusts accountable for their performance,
and it was reported that patients or their representa›
tives seldom consulted or acted on the indicators.
Discussion
Our findings suggest that the CRAG indicators have
helped to raise the level of awareness of quality issues
among trust staff and in some instances may have
alerted providers to specific issues that require further
investigation. However, we also found that the
indicators were rarely used directly to stimulate
continuous quality improvement nor were they used to
identify and share best practice between organisations.
Our findings are based on case studies of only eight
Scottish trusts and, although the sample was selected to
be broadly representative of trusts in Scotland, may not
be applicable to trusts elsewhere in the United
Kingdom. Similarly, our study focused on the impact of
only two clinical indicators, and our findings may have
been different if we had focused on other indicators.
Notwithstanding the above, as the clinical indicators
published under the performance assessment frame›
work in England and Wales are similar to those
published in Scotland, many of our findings relating to
these data may be directly transferable to similar
programmes currently being developed elsewhere in
the United Kingdom. We believe that this is the first in
depth evaluation of the impact of a clinical indicator
programme in a UK context, which makes many of
our findings more directly transferable to the rest of
the NHS.
There have been a limited number of studies based
in the United States that have assessed the impact of
Reasons for low impact of CRAG indicators
Credibility
“One concern is how valid the data are. It is important if you are going to
use data that you have clinical people on board and that they are happy the
data collection is correct. We have a degree of suspicion over some of the
CRAG data that are coming out” (stroke consultant)
Timeliness
“It’s pretty basic information and it comes out several years after it is taken.
Things have changed over that period of time. So, in relation to say
treatment of cervical cancer, the whole way of cancer management has
changed. The change had already occurred by the time the data were
issued” (medical director)
Awareness
“There should be more widespread dissemination of this information [the
CRAG reports]. It would certainly be useful to push it down to my level of
service manager . . . Clinical outcomes don’t just apply to doctors”
(nurse manager)
Training and facilitation
“I don’t think there is sufficient knowledge about CRAG data. It is not
taught in medical schools” (breast surgeon)
Incentives
“The reward [for performing well on the indicators] is for those services
looking for development. It [the CRAG data] is used to help strengthen the
case for change. If you are bidding for capital equipment you can use it to
persuade your case. In terms of sanctions it is a peer one—not letting your
peers down” (chief executive)
Supplementary information
“I don’t think at the current level of accuracy you can pull out that sort of
information [individual clinical performance] from these figures. Poor
performance with doctors tends to be [transmitted] from word of mouth
and other soft information” (stroke consultant)
Process versus outcome indicators
“It is easier to measure the process, it is quicker and more responsive than
outcome data (breast surgeon)
External accountability
“We are not really held to account at all on this set of indicators”
(clinical director)
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the publication of clinical data on provider organisa›
tions. On the whole, these studies have found that pub›
lished clinical indicators rarely stimulate quality
improvement.1–3 7 Our findings indicate several reasons
why published clinical indicators often have little or no
effect in provider organisations. A key lesson of the
Scottish experience is that those responsible for
designing clinical indicator systems should not only
concentrate on developing robust datasets with but
should also encourage a suitable organisational
environment and incentive context to foster the use of
these data for continuous quality improvement.
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Declaring financial competing interests: survey of five
general medical journals
Amina Hussain, Richard Smith
Although many authors of biomedical journal articles
have financial competing interests, they often fail to
disclose them.1–3 Editors have been concerned about
this for a long time. In 1985, the International
Committee of Medical Journal Editors produced a
statement on conflicts of interest, and journal editors
adopted individual policies.4 But how effective have
their policies been in practice?
Krimsky et al investigated the financial interests of
over 1000 authors whose articles appeared in 14 scien›
tific and medical journals in 1992.3 Although 15% of
authors had financial ties relevant to one of their publi›
cations, no voluntary disclosures were published. In
1998, Stelfox et al showed that 23/24 authors (96%)
defending the safety of calcium channel antagonists had
financial ties with manufacturers of these drugs
compared with 11/30 (37%) who were critical of their
use.1 Only 2/70 articles disclosed the authors’ potential
conflicts of interest. These findings confirmed that little
had been achieved since initial concerns had been raised
over a decade earlier. Recently, however, editors have
been paying more attention to the issue and urging
authors to declare competing interests. This study aimed
to find out whether more authors have been doing this.
Methods and results
Using random number tables, we selected six sample
issues of five leading medical journals (Annals of
Internal Medicine, BMJ, JAMA, Lancet, and New England
Journal of Medicine) from each of four years: 1989, 1994,
1996, and 1999. All editorials, papers reporting
original research, and letters were examined to see if
they contained a statement declaring authors’ potential
financial competing interests (this did not include
statements that only mentioned the funding source).
We also examined each journal’s written policy on
financial competing interests (see the BMJ ’s website).
We studied 3642 articles, 52 (1.4%) of which
declared authors’ competing interests: two articles in
1989, eight in 1994, four in 1996, and 38 in 1999. The
papers section had the greatest proportion of declara›
tions (23/656; 3.5%), followed by editorials (7/412;
1.7%), then letters (22/2574; 0.9%) (table).
Comment
After much delay, there are now signs of a small, but
increasing, proportion of articles declaring competing
interests in some journals. Variations in policy require›
What is already known on this topic
Current policy on performance assessment in England and Wales
places a great deal of emphasis on the collection and dissemination of
clinical information
Dissemination of clinical outcome data has had limited impact on the
behaviour of provider organisations in the United States
What this paper adds
Research in Scottish trusts suggests that clinical indicators are rarely
used to stimulate quality improvement or share good practice
The reasons for low impact include internal factors relating to the
properties of the indicators and external factors within the
organisational environment in which the data are used
Written policies on
each of the five
journals are
available on the
BMJ’s website
Papers
BMJ, London
WC1H 9JR
Amina Hussain
Clegg scholar
Richard Smith
editor
Correspondence to:
A Hussain,
Raigmore Hospital,
Inverness IV2 3UJ
hussainamina@
hotmail.com
BMJ 2001;323:263–4
263BMJ VOLUME 323 4 AUGUST 2001 bmj.com
 on 28 April 2005 bmj.comDownloaded from 
